C0632 - Real World Weight Loss Outcomes of Semaglutide in Patients With Overweight and Obesity After Bariatric Surgery

Monday, October 24, 2022

3:00 PM – 5:00 PM ET

Location: Crown Ballroom

Has Audio

Presenting Author(s)

Wissam Ghusn, MD

Mayo Clinic
Rochester, MN

Wissam Ghusn, MD, Khushboo S. Gala, MD, Alan De La Rossa, MD, Lizeth Cifuentes, MD, Daniel Sacoto, MD, Alejandro Campos, MD, Fauzi Feris, MD, Maria D. Hurtado, MD, Andres Acosta, MD, PhD
Mayo Clinic, Rochester, MN

Introduction: Bariatric surgeries have shown to be the most effective weight loss intervention. However, some patients may experience weight recurrence which requires further management. Recent randomized trials demonstrated the effectiveness of semaglutide, a GLP-1 agonist, in achieving weight loss. Little is known about real-world outcomes of semaglutide use in patients with overweight and obesity who underwent bariatric surgeries.

Methods: We performed a retrospective data collection on the use of semaglutide in adults who underwent bariatric surgery (i.e., Roux-en-Y gastric bypass [RYGB] or sleeve gastrectomy [SG]). We included patients with a body mass index ≥27 kg/m² who used any dose of weekly semaglutide subcutaneous injections for ≥3 months after their surgery. We excluded patients taking other anti-obesity medications or with an active malignancy. The primary end point was the total body weight loss percentage (TBWL%), and secondary end points were TBWL% of each of RYGB and SG and the proportion of patients achieving ≥5% and ≥10% TBWL at 3 and 6 months of taking semaglutide. Continuous end points were analyzed using matched paired t test. Data are presented as mean ± standard deviation.

Results: A total of 24 patients who underwent bariatric surgery were included in the analysis (96% female, mean age 48.9± 9.5 years, body-mass index 44.3± 15.4 kg/m²). The median number of years between the bariatric surgery and semaglutide initiation was 8 years. There was a statistical difference in weight loss of 6.3 kg equivalent to a TBWL% of 5.7% (n= 24; p<0.001) at 3 months and a weight loss of 15.0 kg equivalent to 13.0% (n=13; p< 0.001) at 6 months. Patients with RYGB had a TBWL% of 5.5% (n=16) and 13.7% (n=8) while those with SG had 6.1% (n=8) and 11.9% (n=5) at 3 (p=0.69) and 6 months (p=0.58), respectively. In our cohort, 15/24 patients (63%) achieved ≥5% TBWL while 3/24 (13%) achieved ≥10% TBWL% in 3 months. In addition, 13/13 patients (100%) achieved ≥5% TBWL while 7/13 (54%) achieved ≥10% TBWL in 6 months. In our cohort, 10/24 (42%) patients reported experiencing side effects with nausea/vomiting (25%) being the most common.

Discussion: This study demonstrates significant weight loss outcomes of semaglutide in patients after undergoing bariatric surgery. More studies with larger sample size are needed to further evaluate the effectiveness of this medication to counteract the weight recurrence after bariatric surgeries.

Figure: Figure 1: Total body weight change percentage (TBWC%) (A), and categorical TBWL% at 3 and 6 months (B).

Demographic Information	All Patients
N	24
Age, years (SD)	48.9 (10)
Sex, Female (%)	23 (96)
Race, White (%)	18 (75)
Bariatric Surgery
Roux-en-Y gastric bypass, n (%)	16 (67)
Sleeve gastrectomy, n (%)	8 (33)
Baseline Clinical and Laboratory Information
Weight, kg (SD)	118.6 (42.5)
BMI, Kg/m²(SD)	44.3 (15.4)
Overweight, n (%)	1 (4)
Obesity Class 1, n (%)	7 (29)
Obesity Class 2, n (%)	4 (17)
Obesity Class 3, n (%)	12 (50)
SBP, mmHg (SD)	127.7 (21)
DBP, mmHg (SD)	96.7 (22)
Glucose, mg/dL (SD)	112 (38)
HbA1c, % (SD)	5.4 (0.5)
Total Cholesterol, mg/dL (SD)	171.8 (24.7)
Total Triglycerides, mg/dL (SD)	81.8 (31.6)
LDL, mg/dl (SD)	91.5 (24.5)
HDL, mg/dl (SD)	63.7 (12.8)
Obesity Comorbidities
Dyslipidemia, n (%)	6 (25)
Diabetes mellitus, n (%)	2 (8.3)
Hypertension, n (%)	7 (29.2)
GERD, n (%)	9 (37.5)
Obstructive sleep apnea, n (%)	7 (29.2)
NAFLD, n (%)	2 (8.3)
Visits Information
Patients with dietitian visits, n (%)	8 (33.3)
Patients with psychologist visit, n (%)	2 (8.3)
Patients with 3 months follow-up, n (%)	24 (100)
Patients with 6 months follow-up, n (%)	13 (54)
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; GERD, gastroesophageal reflux disease; HbA1c, Hemoglobin A1C; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; NAFLD, Nonalcoholic fatty liver disease; SBP, Systolic blood pressure. Data are presented as mean and standard deviation for continuous variables, and as frequency and percentage for categorical variables.

Table: Table 1: Demographic and clinical information.

Disclosures:

Wissam Ghusn indicated no relevant financial relationships.

Khushboo Gala indicated no relevant financial relationships.

Alan De La Rossa indicated no relevant financial relationships.

Lizeth Cifuentes indicated no relevant financial relationships.

Daniel Sacoto indicated no relevant financial relationships.

Alejandro Campos indicated no relevant financial relationships.

Fauzi Feris indicated no relevant financial relationships.

Maria Hurtado indicated no relevant financial relationships.

Andres Acosta: Gila Therapeutics – Consultant, Intellectual Property/Patents, Owner/Ownership Interest. Phenomix Sciences – Intellectual Property/Patents, Owner/Ownership Interest.

Wissam Ghusn, MD, Khushboo S. Gala, MD, Alan De La Rossa, MD, Lizeth Cifuentes, MD, Daniel Sacoto, MD, Alejandro Campos, MD, Fauzi Feris, MD, Maria D. Hurtado, MD, Andres Acosta, MD, PhD. C0632 - Real World Weight Loss Outcomes of Semaglutide in Patients With Overweight and Obesity After Bariatric Surgery, ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.